vimarsana.com
Home
Live Updates
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis : vimarsana.com
Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
/PRNewswire/ -- CSL Vifor today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin...
Related Keywords
Switzerland
,
Australia
,
Melbourne
,
Victoria
,
Steve Pascoe
,
Vifor International
,
Fresenius Medical Care
,
Dual Endothelin Angiotensin Receptor Antagonist
,
Senior Vice President
,
Therapeutic Area Strategy
,
Efficacy Endpoints
,
Two Year Exploratory Endpoints
,
Travere Therapeutics
,
Vifor Fresenius Medical Care Renal Pharma
,
Vifor International Ag Csl
,
vimarsana.com © 2020. All Rights Reserved.